- Home
- OPT vs BFLY Comparison
OPT vs BFLY Comparison
Compare OPT & BFLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- BFLY
- Stock Information
- Founded
- OPT 1984
- BFLY 2011
- Country
- OPT Australia
- BFLY United States
- Employees
- OPT N/A
- BFLY N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- BFLY Medical Electronics
- Sector
- OPT Health Care
- BFLY Health Care
- Exchange
- OPT Nasdaq
- BFLY Nasdaq
- Market Cap
- OPT 767.9M
- BFLY 750.0M
- IPO Year
- OPT 2020
- BFLY N/A
- Fundamental
- Price
- OPT $3.22
- BFLY $3.12
- Analyst Decision
- OPT Strong Buy
- BFLY
- Analyst Count
- OPT 1
- BFLY 0
- Target Price
- OPT $12.00
- BFLY N/A
- AVG Volume (30 Days)
- OPT 13.0K
- BFLY 3.2M
- Earning Date
- OPT 08-30-2024
- BFLY 11-01-2024
- Dividend Yield
- OPT N/A
- BFLY N/A
- EPS Growth
- OPT N/A
- BFLY N/A
- EPS
- OPT N/A
- BFLY N/A
- Revenue
- OPT $261,859.00
- BFLY $76,221,000.00
- Revenue This Year
- OPT N/A
- BFLY $24.93
- Revenue Next Year
- OPT $46,864.64
- BFLY $18.11
- P/E Ratio
- OPT N/A
- BFLY N/A
- Revenue Growth
- OPT N/A
- BFLY 11.49
- 52 Week Low
- OPT $1.79
- BFLY $0.67
- 52 Week High
- OPT $5.45
- BFLY $3.78
- Technical
- Relative Strength Index (RSI)
- OPT 40.67
- BFLY 49.56
- Support Level
- OPT $3.15
- BFLY $3.28
- Resistance Level
- OPT $3.78
- BFLY $3.77
- Average True Range (ATR)
- OPT 0.18
- BFLY 0.28
- MACD
- OPT -0.00
- BFLY -0.06
- Stochastic Oscillator
- OPT 25.91
- BFLY 6.34
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About BFLY Butterfly Network Inc.
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface.